Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.

Manegold, Philipp C; Paringer, Carmen; Kulka, Ulrike; Krimmel, Klaus; Eichhorn, Martin E; Wilkowski, Ralf; Jauch, Karl-Walter; Guba, Markus; Bruns, Christiane J

Manegold, Philipp C; Paringer, Carmen; Kulka, Ulrike; Krimmel, Klaus; Eichhorn, Martin E; Wilkowski, Ralf; Jauch, Karl-Walter; Guba, Markus; Bruns, Christiane J.

Affiliation

Manegold PC; Department of Surgery and Radiation Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany. Philipp.Manegold@med.uni-muenchen.de

Clin Cancer Res ; 14(3): 892-900, 2008 Feb 01.

Article in En | MEDLINE | ID: mdl-18245553

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Sirolimus/analogs & derivatives; Animals; Cell Division/drug effects; Cell Line, Tumor; Colonic Neoplasms/blood supply; Colonic Neoplasms/drug therapy; Colonic Neoplasms/radiotherapy; Endothelium, Vascular/cytology; Endothelium, Vascular/drug effects; Everolimus; Humans; Mice; Microcirculation/drug effects; Pancreatic Neoplasms/blood supply; Pancreatic Neoplasms/drug therapy; Pancreatic Neoplasms/radiotherapy; Radiation-Sensitizing Agents/pharmacology; Sirolimus/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sirolimus / Angiogenesis Inhibitors Limits: Animals / Humans Language: En Journal: Clin Cancer Res Year: 2008 Document type: Article

Fulltext

XML

PubMed Links

Search on Google